I don't think 40K shares traded in the pre-market so that should tell you I didn't have a big position.
I have no interest in buying & I doubt investors are in a rush before the non-earnings announcement in a few weeks.
Quit trying to blame the MM, shorts, etc., for the lousy price action. This weeks presentation was more of the same fluff they've been selling for the last 10 yrs.
They failed the RCCT a long time ago. The only thing that matters is Sumatriptan is a $2 billion market, Rheumatoid arthritis is a $12 billion market, & the testosterone is another $5 billion. If they only capture 5% of these markets which is more then reasonable then ATRS is worth billions.
Join the Cult.
The ZTS investment was in the news as his next bet following Allergan. I've never looked into it but I'm sure that's a mistake. I may pick up some shares this week as a follow the money trade.
I'm not sure how he's structured his investment but I've never known him to lie to the market.
"Feb 12 (Reuters) - Hedge fund titan William Ackman said on Thursday that U.S. mortgage financing giants Fannie Mae and Freddie Mac are a bet he likes a lot.
"It is the most interesting risk-reward that I am aware of in the capital markets right now," Ackman said at the Harbor Investment Conference when asked to discuss his investement in the the two companies."
Mo, I'll be investing in FNMA & FMCC on Monday. If Achman says they're the best risk reward stocks he knows then that's good enough for me. I've started to follow the smart money with some of my investments. Recently invested in ebay since Ichan's been a big investor & activist.
I call pathetic anyone who says a $30 million a year drug is a MONSTER when a company will have 150 million shares?
Blues, the difference between you & me is that I'll still point out the negatives even when I hold shares. I don't set unrealistic expectations or let emotions guide my feeling about a company.
This weeks numbers were the first signs of life for Otrexup in awhile so maybe the new sales program is working. If they can remove the Medac litigation risk & continue to show some growth in the Otrexup numbers then I'll even admit $5 is an easy target.
One other thing - The FDA took Mivacron off the market in 2006 for the exact reasons approval of Sugammadex has been denied up to this point. Anesthesia providers have no interest/reason to administer a drug which increases the chances for a hypersensitivity reaction.
"Sugammadex: A revolutionary drug in neuromuscular pharmacology"
Conclusion : Sugammadex may potentially promote the increased use of non-depolarizing aminosteroid muscle relaxants, but economic constraints may prevent its wide spread use and poses great limitations to its use.
I give anesthesia for a living & I can tell you that Sugammadex will not be used but in rare instances. There's just no need in 99.99% of cases.